Biohaven (BHVN) stock

Market cap $2.0B

$13.14

-1.57%

Market closed. Prices as of Thursday's close.

Quality Score

-3

Poor

In its industry

#189of 276

Biotech

Checks firing

1of 14

Choppy

From 52-week high

-29.2%

Below the 200-day

Next2H 2026“Dosing continues in BHV7000-303 and topline data remain on track for the second half of 2026.”Trial data · 8-K, Sep 10

Cash$268M, about 2 quarters at the last year's spendingOn Jun 30

Follow BHVN's trial news. Pro members can get an alert when Biohaven files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when BHVN files news on its trialsFree for 24 hours. No account needed.

Cash$268M, about 2 quarters at the last year's spendingOn Jun 30

Pipeline and cash

What's next for BHVN, and how long its cash lasts

From Biohaven’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2H 2026“Dosing continues in BHV7000-303 and topline data remain on track for the second half of 2026.”Trial data · 8-K, Sep 10

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: BHV7000
Another trial: RISE 3Phase 2/3 · Active · 390 people · main data estimated Oct 2026 · NCT06309966

11 more trials, 3 with data due this year, 2 more milestones and 41 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 2 quarters

$268M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed May 4, 2026)
At-the-market share sales program (S-3ASR, filed May 4, 2026)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

An officer, George C. Clark, bought 17,000 shares on Nov 17, 2025.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Vlad Coric buys or sells

For Pro members: every trade, and Vlad Coric’s 5 filings and quotes.

Get an optional alert when BHVN files news on its trialsFree for 24 hours. No account needed.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 28 daysFDA decisionIn 28 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $122MINO-3107Under FDA review
In 39 daysANDA decisionIn 39 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $130MDrug not namedA generic, under FDA review
In 51 daysFDA decisionIn 51 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $486MDrug not namedUnder FDA review

8 more FDA dates and 107 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Quality Score

Why BHVN scores -3

PoorChoppy, 1 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

+1Chart checks 1 of 14 firing right now, one point each
−2Dilution 47.1% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Long-term trend subtracts
Run-up adds
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Profit, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on BHVN and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 1:11 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Fri Oct 23: European Society of Medical…Industry event · date confirmed.

Expected to report Mon Nov 9, after the close

After its last 4 reports it closed -5.0% on average, higher 0 of 4 times.

1 more date ahead for Pro members: the conference

What would turn BHVN's score around: 8 things, for Pro members

Alert me when BHVN's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A Pro member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the chart checks bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest — A card on the scanner, shown on AMD

A Pro member's stock page for AMD: the Quality Score with its rank, the checks firing, and the reason behind it, the live price, and the chart — A stock page

The scanner a Pro member sees: every stock as a card with its Quality Score, rank, and chart checks bar, and the watchlist — The scanner

The 14 checks

BHVN has 1 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on BHVN, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

RSI 1444.7
Above 30, below 50.
MACD (12, 26, 9)Below signal
Crossed below its signal line 5 sessions ago.
50-day average$14.13
The price is 7.0% below it.
200-day average$12.03
The price is 9.2% above it. The 50-day is above the 200-day, since Jul 9.
ADX 1414.7
Under 25, with +DI below -DI.
Support$13.13
Swing low from Jul 30, 0.1% below the price.
Resistance$14.01
Swing high from Jan 23, 6.6% above the price.
Bollinger Bands (20, 2)Inside
The bands run from $11.56 to $15.77.
Volume0.5x
Against its 20-day average, for the time of day.

Its industry

How BHVN ranks in Biotech

BHVN is #189 of 276 by Quality Score. The top three are shown with their scores, and more by name.

1KNSAKiniksa Pharmaceuticals International7/1418
2ABCLAbCellera Biologics6/1416
3OABIOmniAb9/1415
BCYCBicycle TherapeuticsOpen for its score
BEAMBeam TherapeuticsOpen for its score
BIIBBiogenOpen for its score
BIOABioAge LabsOpen for its score
189BHVNBiohaven1/14-3

When does BHVN report earnings, and what happens after?

Expected to report Mon Nov 9, after the close (in 38 days). Not yet confirmed by the company.

-5.7%-9.7%-4.2%-0.3%

Nov 10Mar 2May 4Aug 10

Reported	When	Gap	Reaction	5 sessions
Aug 10, 2026After close	After close	-3.7%	-0.3%	-0.6%
May 4, 2026After close	After close	+0.1%	-4.2%	-10.4%
Mar 2, 2026After close	After close	-3.2%	-9.7%	-13.6%
Nov 10, 2025Before open	Before open	+2.3%	-5.7%	+0.5%

The gap is the next open against the close before the report; the reaction is where that session closed. BHVN closed higher after 0 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

The company

About Biohaven

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

274 employeesNew Haven, CTbiohaven.com

Pro

Every line of the score, on every stock.

Real-time prices, no delay
Every line of BHVN's score, with the points and the reason
All 14 checks on BHVN and on all 2,958 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on BHVN

See all 14 checks on BHVNFree for 24 hours. No account needed. Then keep going with a free account.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.